

CANNAVID - Study on the impact of Covid-19 on use, practices and health among regular cannabis users

Head :Roux Perrine , UMR 1252 SESSTIM

Last update : 05/06/2021 | Version : 1 | ID : 73876

General	
Identification	
Detailed name	Study on the impact of Covid-19 on use, practices and health among regular cannabis users
Sign or acronym	CANNAVID
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation	CNIL 2217595
General Aspects	
Medical area	Infectious diseases Psychology and psychiatry
Study in connection with Covid-19	Yes
Pathology (details)	addiction, inflammatory diseases, psychiatric disorders, cardiac or vascular disease, obesity or other metabolic disease, respiratory diseases, infectious diseases, cancer
Health determinants	Addictions Healthcare system and access to health care services Lifestyle and behavior Occupation Social and psychosocial factors
Keywords	Cannabis and other illicit substances, Covid-19, mental health, pain, lockdown
Scientific investigator(s) (Contact)	
Name of the director	Roux
Surname	Perrine
Address	Sciences Economiques et Sociales de la Santé et

Traitement de l'Information Médicale
Faculté de
médecine
27 bd Jean Moulin
13005
Marseille

Phone +33(0)4 13 73 22 78

Email perrine.roux@inserm.fr

Unit UMR 1252 SESSTIM

Organization Inserm

Collaborations

Participation in projects,
networks and consortia No

Funding

Funding status Mixed

Details no funding for this study

Governance of the database

Sponsor(s) or organisation(s)
responsible Bus 31/32 Association (CSAPA, CAARUD)

Organisation status Private

Presence of scientific or
steering committees Yes

Labelling and database
evaluation internal audit

Additional contact

Name of the contact Lebrun Gadelius

Surname Maela

Address Bus 31/32
4 avenue Rostand
13003
Marseille

Phone 04 95 04 56 06

Email maela.lebrun@bus3132.org

Organization Bus 31/32

Main features

Type of database

Type of database	Study databases
Study databases (details)	Repeated cross-sectional studies (except case control studies)
Database recruitment is made on the basis of:	Another treatment or procedure
Database recruitment is carried out as part of an interventional study	No
Additional information regarding sample selection.	Promotion of the study via different websites aimed at cannabis users (patient or harm reduction associations, social network).

Database objective

Main objective	Evaluate the impact of the different lockdowns on cannabis use practices among daily users, psychoactive substance use and the onset of related symptoms (withdrawal, pain, sleep disorders, anxiety, depression).
Inclusion criteria	Daily cannabis users or individuals having taken part in the previous CANNAVID series for questionnaires completed from the second lockdown; Aged over 18 years; Able to understand French; Residing in France; Agreeing to take part in the study and having expressed their non-objection.

Population type

Age	Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more)
-----	---

Population covered	General population
--------------------	--------------------

Pathology

Gender	Male Woman Other
--------	------------------------

Geography area	National
----------------	----------

Detail of the geography area	France
Data collection	
Dates	
Date of first collection (YYYY or MM/YYYY)	2020
Date of last collection (YYYY or MM/YYYY)	2020
Size of the database	
Size of the database (number of individuals)	[1000-10 000[individuals
Details of the number of individuals	First lockdown: 4,019 participants
Data	
Database activity	Current data collection
Type of data collected	Declarative data
Declarative data (detail)	Internet self-questionnaire
Details of collected declarative data	Sociodemographic characteristics (age, gender, level of education, accommodation, parenthood), before and during the lockdown (accommodation, professional activity, recourse to a food bank); psychoactive substance use (use, supply, storage, quantities used, adverse reactions, withdrawal symptoms, substance analyses, penalties due to cannabis use) before and during the lockdown, changes in use between lockdowns; health status and practices (chronic disorders, treatments, symptoms of Covid-19, overdoses, medical appointments, Hospital Anxiety and Depression scale before and during the lockdown.
Presence of a biobank	No
Health parameters studied	Health event/morbidity Quality of life/health perception
Quality of life/perceived health (detail)	state of health before and during the lockdown
Procedures	

Data collection method	Data collection via the internet
Classifications used	Hospital Anxiety and Depression scale, withdrawal symptoms (American Psychiatric Association 2013), ICD-10
Quality procedure(s) used	methodology centre specialised in epidemiological studies
Participant monitoring	Yes
Details on monitoring of participants	please state whether the participant took part in the first questionnaire series
Followed pathology	F10-F19 - Mental and behavioural disorders due to psychoactive substance use
Links to administrative sources	No

Promotion and access

Promotion

Link to the document	https://www.cairn.info/revue-psychotropes-2020-2-page-141.htm
Description	CANNAVID survey: Changes in cannabis use among daily users during the Covid-19 pandemic

Other information	Preliminary results available on: https://infogram.com/cannavid-resultats-preliminaires-1hzj4onmnjlo2pw?live
-------------------	--

Access

Dedicated website	https://cannavid.limequery.com/439624?lang=fr
Presence of document that lists variables and coding procedures	Yes
Terms of data access (charter for data provision, format of data, availability delay)	Methods for accessing the database are in the process of being defined
Access to aggregated data	Access on specific project only
Access to individual data	Access on specific project only